Live data from Hacker News

I was in the MAPS MDMA for PTSD study

psymposia.com

51–60 of 159 posts

Re: I was in the MAPS MDMA for PTSD study

#51
post #3

If anyone is interested in learning more about this stuff, the annual Horizons conference is this weekend in NYC: http://www.horizonsnyc.org And there will most likely be a MAPS event on Saturday night as well. I'm not going this year, but in previous years they've always been good.

Yes: MAPS is hosting a benefit dinner for psychedelic research on Saturday (tomorrow) night http://www.maps.org/nyc2017

Re: I was in the MAPS MDMA for PTSD study

#52
post #19

Earlier quoted context omitted.

Was the threat to the traditional American way of life really the reason they were made illegal? It seems more likely that it was due to the unknown and possibly dangerous nature of the drugs. As a society we have always outlawed drugs that can drastically alter perception (aside from alcohol).

I don't think there's a firm consensus on the reasoning, but it's generally acknowledged that the Sch. 1 classification of the psychedelics was motivated to 1) quell their threat of cultural and political destabilization and 2) to keep hippies and blacks in check. The 60s were similar to Occupy Wall Street: there's major (valid) fear on the part of the establishment when a radically different movement picks up steam.…

>there's major (valid) fear on the part of the establishment when a radically different movement picks up steam

What do you mean by "valid" here? Do you mean they are afraid for society, or themselves?

Re: I was in the MAPS MDMA for PTSD study

#53
post #43
post #39

Earlier quoted context omitted.

When a patient sits with a therapist under the influence of MDMA, which typically consists of two doses (100-120mg initially, then 70mg a few hours later) spread over an 6-8 hour period. The patient is largely experiencing their own internal process, but at times the therapist is there to help guide and comfort. Before and after the session there is conventional psychotherapeutic follow-up.

Are you sure about the doses? Doesn't sound overly therapeutic to me tbh

Sometimes the second dose is lower, but this is the typical ballpark which is supported by research.

Re: I was in the MAPS MDMA for PTSD study

#54
post #21

Every time articles like this appear on Hacker News it fills me with joy. I have personally watched a much older person heal extensive personal trauma with just one MDMA session, and to this day I regard it as a miracle that seemed impossible prior to the treatment. MAPS is just entering into their Stage III research process after being granted a "breakthrough therapy" by the FDA ( https://www.cbsnews.com/news/fda-de…

Yes. The main barrier to more psychedelic research is funding / $$ and time - far more than anything else.

In the US, access to research funding is a far larger issue than scheduling. The main benefit of rescheduling would likely be through its indirect benefits on access to funding.

Source: I’ve talked with multiple researchers who are studying psychedelics.

Also, I recommend reading or listening to the book Acid Test if anyone here would like to learn more.

Re: I was in the MAPS MDMA for PTSD study

#55

Earlier quoted context omitted.

What is an MDMA session?

A short web page I put together with some more info: https://rollsafe.org/mdma-therapy/

Hi, your link looks interesting so thanks for putting that together but I just wanted to say it seems you've set the CSS property word-wrap: break-word on all elements of your site, which makes it kind of hard to read the text as words are constantly being chopped off.

Re: I was in the MAPS MDMA for PTSD study

#56
If anyone on Hacker News would like a crash course on the history and potential of psychedelic substances - I cannot recommend the book Acid Test by Tom Shroder more highly.

Or, for a shorter view, the article Trip Treatment by Michael Pollan: https://www.newyorker.com/magazine/2015/02/09/trip-treatment

Re: I was in the MAPS MDMA for PTSD study

#58
post #55

Earlier quoted context omitted.

A short web page I put together with some more info: https://rollsafe.org/mdma-therapy/

Hi, your link looks interesting so thanks for putting that together but I just wanted to say it seems you've set the CSS property word-wrap: break-word on all elements of your site, which makes it kind of hard to read the text as words are constantly being chopped off.

Thanks for the comment. Can you share a screenshot on imgur.com by any chance? I can't reproduce the issue so would like to know what you're seeing so I can fix it.

Re: I was in the MAPS MDMA for PTSD study

#59
post #39

Earlier quoted context omitted.

When a patient sits with a therapist under the influence of MDMA, which typically consists of two doses (100-120mg initially, then 70mg a few hours later) spread over an 6-8 hour period. The patient is largely experiencing their own internal process, but at times the therapist is there to help guide and comfort. Before and after the session there is conventional psychotherapeutic follow-up.

Is it possible to do this, today, anywhere in the world (without getting into a study, which seems hard, especially in another country)? I am looking for help for somebody close to me.

Only if you know a willing therapist.

Re: I was in the MAPS MDMA for PTSD study

#60
post #8

Earlier quoted context omitted.

> For decades, there has been a near complete effective block on medical research for certain classes of drugs. In the US. One wonders why such a study wasn't carried out in a less puritan country.

It's because the real reason that testing these drugs is illegal isn't USA puritan values/laws. It's because they aren't patented. The synthetic opioids that drug companies are dumping on the population these days are many times more dangerous, but they make a profit for big companies, so they are legal. Powerful drug companies influence research worldwide. They want no competition from drugs that would be generic fr…

It’s true in general that economics, with patents being part of that, is the dominant influence on r&d resources.

However the effective research ban is by far the bigger limiting factor in this case, because it rules out most options before even getting started.

For example, it’s not unusual for unpatentable substances to be studied, in the hope that understanding the fundamental mechanism could allow a (sometimes) improved alternative to be developed that could be profitable.

There is also at least some research not controlled by big pharma that could have conceivably targeted these areas 40 years ago.

Post reply on HN